Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients

26 Oct 2018

Abstract excerpt

Waldenstrom macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma associated with immunoglobulin M monoclonal gammopathy. In this study, we describe the impact of CXCR4 mutations on progression-free survival and overall survival of WM patients under treatment with a bortezomib-based combination and attempt to frame that in the context of pan-cancer data on CXCR4 expression and bortezomib sensitivity.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Immunodeficiency and Autoimmune Disorders
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30366921
DOI: 10.1182/blood-2018-07-863241

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patientsPMID 30366921Read ↗

Waldenström macroglobulinemia: a review of pathogenesis, current treatment, and future prospects.Semantic proximity Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

Current therapy guidelines for Waldenstrom's macroglobulinaemia.Semantic proximity Read ↗

Toward personalized treatment in Waldenström macroglobulinemia.Semantic proximity Read ↗

Emerging drugs for the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

Advances in Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

The Direction of Modern Therapies in Waldenström Macroglobulinaemia.Semantic proximity Read ↗

New treatment strategies for Waldenström macroglobulinemia.Semantic proximity Read ↗

Significances of MYD88L265P and CXCR4WHIM Mutations in Waldenstrom Macroglobulinemia.Semantic proximity Read ↗

Current approach to Waldenström Macroglobulinemia.Semantic proximity Read ↗

How to Sequence Therapies in Waldenström Macroglobulinemia.Semantic proximity Read ↗

Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.